Daily Stock Analysis, CBLI, Cleveland Biolabs Inc, priceseries

Cleveland Biolabs Inc. Daily Stock Analysis
Stock Information
Open
3.32
Close
3.38
High
3.40
Low
3.27
Previous Close
3.36
Daily Price Gain
0.02
YTD High
5.55
YTD High Date
Apr 19, 2017
YTD Low
1.35
YTD Low Date
Mar 17, 2017
YTD Price Change
1.93
YTD Gain
133.10%
52 Week High
5.55
52 Week High Date
Apr 19, 2017
52 Week Low
1.22
52 Week Low Date
Dec 29, 2016
52 Week Price Change
0.86
52 Week Gain
34.13%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 26. 2015
3.25
May 27. 2015
3.69
1 Trading Days
13.69%
Link
LONG
Jun 25. 2015
5.38
Jun 26. 2015
5.71
1 Trading Days
6.04%
Link
LONG
Aug 28. 2015
3.80
Sep 25. 2015
4.67
19 Trading Days
23.03%
Link
LONG
Apr 21. 2017
4.00
Apr 24. 2017
4.23
1 Trading Days
5.87%
Link
LONG
May 19. 2017
3.43
May 25. 2017
3.61
4 Trading Days
5.17%
Link
Company Information
Stock Symbol
CBLI
Exchange
NasdaqCM
Company URL
http://www.cbiolabs.com
Company Phone
(716) 849-6810
CEO
Yakov Kogan
Headquarters
New York
Business Address
73 HIGH STREET, BUFFALO, NY 14203
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001318641
About

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company, with a focus on oncology and acute radiation syndrome drug development. It is engaged in the research, development and commercialization of products that have the potential to treat cancer which reduces death from total body irradiation and counteract the toxic effects of radio and chemotherapies for oncology patients. The company has designed two oppositely-directed general therapeutic concepts: temporary and reversible suppression of apoptosis in normal cells to protect healthy tissues from stress-induced damage using compounds categorized as Protectans; and reactivation of apoptosis in tumor cells to eliminate cancer using compounds categorized as Curaxins. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY.

Description

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company's advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.